###begin article-title 0
C5 deficiency and C5a or C5aR blockade protects against cerebral malaria
###end article-title 0
###begin p 1
###xml 30 50 30 50 <email xmlns:xlink="http://www.w3.org/1999/xlink">kevin.kain@uhn.on.ca</email>
CORRESPONDENCE Kevin C. Kain: kevin.kain@uhn.on.ca
###end p 1
###begin p 2
This article is distributed under the terms of an Attribution-Noncommercial-Share Alike-No Mirror Sites license for the first six months after the publication date (see ). After six months it is available under a Creative Commons License (Attribution-Noncommercial-Share Alike 3.0 Unported license, as described at ).
###end p 2
###begin p 3
###xml 36 54 36 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium berghei</italic>
###xml 469 471 469 471 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C5</italic>
###xml 496 498 496 498 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C5</italic>
###xml 555 557 555 557 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C5</italic>
###xml 740 742 740 742 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C5</italic>
###xml 858 860 858 860 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C5</italic>
###xml 942 944 942 944 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C5</italic>
###xml 946 948 946 948 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C5</italic>
###xml 1003 1005 1003 1005 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C5</italic>
###xml 1224 1237 1224 1237 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum</italic>
###xml 1362 1365 1362 1365 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C5/</italic>
###xml 26 30 <span type="species:ncbi:10090">mice</span>
###xml 36 54 <span type="species:ncbi:5821">Plasmodium berghei</span>
###xml 413 417 <span type="species:ncbi:10090">mice</span>
###xml 438 442 <span type="species:ncbi:10090">mice</span>
###xml 892 896 <span type="species:ncbi:10090">mice</span>
###xml 966 970 <span type="species:ncbi:10090">mice</span>
###xml 1024 1028 <span type="species:ncbi:10090">mice</span>
###xml 1115 1119 <span type="species:ncbi:10090">mice</span>
###xml 1224 1237 <span type="species:ncbi:5833">P. falciparum</span>
Experimental infection of mice with Plasmodium berghei ANKA (PbA) provides a powerful model to define genetic determinants that regulate the development of cerebral malaria (CM). Based on the hypothesis that excessive activation of the complement system may confer susceptibility to CM, we investigated the role of C5/C5a in the development of CM. We show a spectrum of susceptibility to PbA in a panel of inbred mice; all CM-susceptible mice examined were found to be C5 sufficient, whereas all C5-deficient strains were resistant to CM. Transfer of the C5-defective allele from an A/J (CM resistant) onto a C57BL/6 (CM-susceptible) genetic background in a congenic strain conferred increased resistance to CM; conversely, transfer of the C5-sufficient allele from the C57BL/6 onto the A/J background recapitulated the CM-susceptible phenotype. The role of C5 was further explored in B10.D2 mice, which are identical for all loci other than C5. C5-deficient B10.D2 mice were protected from CM, whereas C5-sufficient B10.D2 mice were susceptible. Antibody blockade of C5a or C5a receptor (C5aR) rescued susceptible mice from CM. In vitro studies showed that C5a-potentiated cytokine secretion induced by the malaria product P. falciparum glycosylphosphatidylinositol and C5aR blockade abrogated these amplified responses. These data provide evidence implicating C5/C5a in the pathogenesis of CM.
###end p 3
###begin p 4
###xml 47 65 47 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium berghei</italic>
###xml 72 74 72 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pf</italic>
###xml 79 92 79 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum</italic>
###xml 47 65 <span type="species:ncbi:5821">Plasmodium berghei</span>
###xml 79 92 <span type="species:ncbi:5833">P. falciparum</span>
Abbreviations used: CM, cerebral malaria; PbA, Plasmodium berghei ANKA; PfGPI, P. falciparum glycosylphosphatidylinositol; TLR, Toll-like receptor.
###end p 4
###begin p 5
P. Gros and K.C. Kain contributed equally to this work.
###end p 5
###begin p 6
###xml 170 171 170 171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib1">1</xref>
###xml 173 174 173 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib2">2</xref>
Despite the development of more potent antimalarial drugs, there has been little progress in identifying interventions that improve the outcome of cerebral malaria (CM) (1, 2). This may be attributable, at least partly, to the observation that severe malaria syndromes such as CM appear to be primarily mediated by host responses to infection rather than by the parasite directly.
###end p 6
###begin p 7
###xml 56 74 56 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmodium berghei</italic>
###xml 283 296 283 296 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum</italic>
###xml 536 537 536 537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib3">3</xref>
###xml 538 539 538 539 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib5">5</xref>
###xml 661 662 661 662 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib6">6</xref>
###xml 663 664 663 664 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib7">7</xref>
###xml 46 50 <span type="species:ncbi:10090">mice</span>
###xml 56 74 <span type="species:ncbi:5821">Plasmodium berghei</span>
###xml 283 296 <span type="species:ncbi:5833">P. falciparum</span>
###xml 310 316 <span type="species:ncbi:9606">humans</span>
###xml 318 322 <span type="species:ncbi:10090">mice</span>
###xml 357 361 <span type="species:ncbi:10090">mice</span>
###xml 558 562 <span type="species:ncbi:10090">mice</span>
Experimental infection of inbred and congenic mice with Plasmodium berghei ANKA (PbA) provides a well-established model to identify host genetic determinants that regulate both protective immunity and infection-associated immunopathology, including the development of CM. Similar to P. falciparum infection in humans, mice susceptible to PbA (e.g., C57BL/6 mice) develop symptoms of severe malaria and CM, including cytokine-associated encephalopathy, acidosis, coagulopathy, shock, and pulmonary edema, culminating in a fatal outcome (3-5). Conversely, A/J mice, although equally susceptible to PbA infection, are more resistant to the associated CM syndrome (6-7).
###end p 7
###begin p 8
###xml 301 302 294 295 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib4">4</xref>
###xml 304 305 297 298 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib8">8</xref>
###xml 306 308 299 301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib12">12</xref>
###xml 584 586 577 579 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib10">10</xref>
###xml 588 590 581 583 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib13">13</xref>
###xml 591 593 584 586 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib15">15</xref>
###xml 765 767 758 760 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib10">10</xref>
###xml 991 992 984 985 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib2">2</xref>
###xml 994 996 987 989 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib15">15</xref>
###xml 254 259 <span type="species:ncbi:9606">human</span>
Excessive or dysregulated inflammatory responses to malaria, including high levels of TNF/lymphotoxin-alpha or inadequate production of regulatory (antiinflammatory) cytokines such as TGF-beta and IL-10, are associated with the development of CM in both human infections and rodent models of disease (4, 8-12). High levels of inflammatory cytokines are associated with endothelial cell activation and increased expression of adhesion molecules that contribute to the sequestration of parasitized erythrocytes and leukocytes in the cerebral vascular bed and the resultant CM syndrome (10, 13-15). Although it is well established that host response contributes to the development of CM, the underlying genetic determinants of susceptibility are poorly characterized (10). A detailed understanding of the host genetic factors that contribute to susceptibility or resistance to CM may facilitate the identification of novel interventions to modulate host response and improve the outcome of CM (2, 15).
###end p 8
###begin p 9
###xml 108 110 108 110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib16">16</xref>
###xml 381 383 381 383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib17">17</xref>
###xml 385 387 385 387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib18">18</xref>
###xml 474 476 474 476 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib19">19</xref>
The complement system is an essential component of the innate immune response to several infectious agents (16). The complement cascade can be activated by four different pathways, three of which converge at the level of the C3 component, leading to the cleavage of C3 and C5 to their activated forms, C3a and C5a, as well as the formation of the terminal membrane attack complex (17, 18). A recently described pathway results in the generation of C5a in the absence of C3 (19).
###end p 9
###begin p 10
###xml 298 300 298 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib16">16</xref>
###xml 302 304 302 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib18">18</xref>
###xml 306 308 306 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib20">20</xref>
###xml 457 459 457 459 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib19">19</xref>
###xml 461 463 461 463 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib21">21</xref>
###xml 464 466 464 466 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib24">24</xref>
###xml 1004 1006 1004 1006 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib16">16</xref>
###xml 1008 1010 1008 1010 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib18">18</xref>
###xml 1012 1014 1012 1014 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib20">20</xref>
A growing body of evidence has implicated excessive activation of the complement system, especially formation of the potent proinflammatory anaphylatoxin C5a in mediating deleterious host responses to bacterial infections and contributing to the development of sepsis, adverse outcomes, and death (16, 18, 20). Blockade of C5a activity or C5aR with antibodies or C5aR antagonists in animal models of sepsis prevents multiorgan injury and improves survival (19, 21-24). Generation of C5a is normally tightly regulated, and under controlled conditions, local production of C5a can enhance effector function of macrophages and neutrophils and contribute to an effective innate response to infection. However, detectable systemic C5a suggests a loss of regulation of complement activation. Elevated C5a levels are associated with several deleterious effects on host innate defense, including defective phagocyte and endothelial cell function, robust chemokine and cytokine secretion, and lymphoid apoptosis (16, 18, 20).
###end p 10
###begin p 11
###xml 145 147 145 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C5</italic>
###xml 532 534 532 534 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C5</italic>
###xml 412 416 <span type="species:ncbi:10090">mice</span>
Similar to sepsis, CM is believed to be the result, at least partly, of a dysregulated inflammatory response to infection. However, the roles of C5 and C5a in the pathogenesis of CM have not been studied. We hypothesized that excessive generation of C5a in response to infection confers susceptibility to CM and investigated the role of C5a in the development of CM in vivo. Using a panel of inbred and congenic mice, we demonstrate a spectrum of differential susceptibility to CM that is associated with the presence or absence of C5 and the generation of C5a, as well as the engagement of C5aR. These data provide direct evidence indicating that C5a plays a role in the pathogenesis of CM in the PbA model.
###end p 11
###begin title 12
RESULTS
###end title 12
###begin title 13
###xml 38 42 <span type="species:ncbi:10090">mice</span>
Differential susceptibility of inbred mice to PbA-induced experimental CM
###end title 13
###begin p 14
###xml 336 337 336 337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib6">6</xref>
###xml 339 340 339 340 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib7">7</xref>
###xml 342 344 342 344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib25">25</xref>
###xml 345 347 345 347 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib27">27</xref>
###xml 698 705 698 705 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="tbl1">Table I</xref>
###xml 710 718 710 718 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 A</xref>
###xml 821 822 819 820 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 867 875 865 873 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 A</xref>
###xml 980 981 978 979 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib6">6</xref>
###xml 983 984 981 982 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib7">7</xref>
###xml 986 988 984 986 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib25">25</xref>
###xml 989 991 987 989 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib27">27</xref>
###xml 1092 1099 1090 1097 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="tbl1">Table I</xref>
###xml 1104 1112 1102 1110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 A</xref>
###xml 1335 1343 1333 1341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 C</xref>
###xml 1394 1395 1390 1391 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 1561 1562 1555 1556 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 1595 1603 1589 1597 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 C</xref>
###xml 1883 1891 1877 1885 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 B</xref>
###xml 2151 2159 2145 2153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 B</xref>
###xml 57 61 <span type="species:ncbi:10090">mice</span>
###xml 211 215 <span type="species:ncbi:10090">mice</span>
###xml 238 242 <span type="species:ncbi:10090">mice</span>
###xml 508 512 <span type="species:ncbi:10090">mice</span>
###xml 781 785 <span type="species:ncbi:10090">mice</span>
###xml 1152 1156 <span type="species:ncbi:10090">mice</span>
###xml 1177 1181 <span type="species:ncbi:10090">mice</span>
###xml 1210 1214 <span type="species:ncbi:10090">mice</span>
###xml 1448 1452 <span type="species:ncbi:10090">mice</span>
###xml 1842 1846 <span type="species:ncbi:10090">mice</span>
###xml 1953 1957 <span type="species:ncbi:10090">mice</span>
###xml 1975 1979 <span type="species:ncbi:10090">mice</span>
Previous studies have established that inbred strains of mice such as C57BL/6 are susceptible to PbA infection and develop symptoms of experimental CM and rapidly succumb to infection. In contrast, other inbred mice, such as DBA/2 or A/J mice, are more resistant to CM and display enhanced survival during the acute phase of infection (6, 7, 25-27). To more completely define the phenotypic expression of differential susceptibility in this experimental model, we simultaneously challenged a panel of inbred mice under carefully controlled experimental conditions with a uniform inoculum of PbA and examined parasitemia, the development of experimental CM, and survival over a course of infection (Table I and Fig. 1 A). We observed differences in survival between A/J and C57BL/6 mice (A/J vs. C57BL/6: P = 0.002 and chi2 = 9.879 using a log-rank test for survival; Fig. 1 A). However, in this analysis a broader spectrum of susceptibility was observed than previously reported (6, 7, 25-27). This phenotypic expression ranged from highly susceptible to highly resistant to experimental CM (Table I and Fig. 1 A). Compared with CM-susceptible C57BL/6 mice, highly susceptible mice such as 129sv/J and 129P3/J mice had an earlier onset of neurological symptoms and succumbed significantly sooner to CM (as confirmed by histopathology; Fig. 1 C) during the course of infection (P = 0.001 and chi2 = 11.317 using a log-rank test). In contrast, AKR/J mice were highly resistant, with significantly improved survival compared with other strains (P = 0.00001 and chi2 = 13.568 using a log-rank test; Fig. 1 C). To examine whether parasite burden contributed to these different phenotypes, we examined the parasitemia in these inbred lines. No significant difference in parasitemia was observed between susceptible, resistant, and highly resistant mice throughout the course of infection (Fig. 1 B and Fig. S1, available at ). In contrast, highly susceptible mice, such as 129sv/J mice, developed significantly higher parasite burdens earlier in the course of infection, as indicated by day 6 peripheral parasitemias (P = 0.006 using a Kruskal-Wallis test; Fig. 1 B).
###end p 14
###begin p 15
###xml 67 69 67 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C5</italic>
PbA-induced experimental CM is associated with the presence of the C5 gene
###end p 15
###begin p 16
###xml 276 277 276 277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib6">6</xref>
###xml 279 280 279 280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib7">7</xref>
###xml 916 918 916 918 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib26">26</xref>
###xml 919 921 919 921 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib28">28</xref>
###xml 23 27 <span type="species:ncbi:10090">mice</span>
###xml 387 391 <span type="species:ncbi:10090">mice</span>
###xml 515 520 <span type="species:ncbi:10090">mouse</span>
CM phenotype describes mice that were judged as developing CM if they displayed neurological symptoms including mono-, hemi-, para-, or tetraplegia, movement disorder, ataxia, hunching, convulsions, and coma, and succumbed to infection by day 12 after inoculation (references 6, 7). Susceptible strains developed neurological symptoms within 6-10 d after inoculation. Highly susceptible mice showed both a significantly higher parasite density and an early onset of neurological symptoms and death than susceptible mouse strains. Resistant strains displayed a significantly delayed onset of neurological symptoms and improved survival compared with susceptible groups. Highly resistant strains did not develop neurological symptoms and displayed enhanced survival compared with resistant strains. Strains analyzed in this study are bolded. Other strains (italicized) were derived as previously described (references 26-28).
###end p 16
###begin p 17
###xml 0 59 0 59 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Differential susceptibility to PbA-induced experimental CM.</bold>
###xml 389 390 387 388 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 526 527 522 523 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 717 718 711 712 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 824 825 818 819 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1220 1221 1214 1215 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 85 89 <span type="species:ncbi:10090">mice</span>
###xml 272 276 <span type="species:ncbi:10090">mice</span>
###xml 345 349 <span type="species:ncbi:10090">mice</span>
###xml 438 442 <span type="species:ncbi:10090">mice</span>
###xml 486 490 <span type="species:ncbi:10090">mice</span>
###xml 577 581 <span type="species:ncbi:10090">mice</span>
###xml 831 835 <span type="species:ncbi:10090">mice</span>
###xml 883 887 <span type="species:ncbi:10090">mice</span>
###xml 983 987 <span type="species:ncbi:10090">mice</span>
###xml 1001 1005 <span type="species:ncbi:10090">mice</span>
###xml 1088 1092 <span type="species:ncbi:10090">mice</span>
###xml 1226 1230 <span type="species:ncbi:10090">mice</span>
###xml 1440 1444 <span type="species:ncbi:10090">mice</span>
###xml 1571 1575 <span type="species:ncbi:10090">mice</span>
Differential susceptibility to PbA-induced experimental CM. The phenotypes of inbred mice strains infected with PbA range from highly susceptible (early onset of cerebral symptoms and high parasitemia) to highly resistant (very little mortality caused by CM). (A) 129sv/J mice were highly susceptible and died significantly earlier than C57BL/6 mice (C57BL/6 vs. 129sv/J: P = 0.001 and chi2 = 9.879 using a Mantel-Cox log-rank test). A/J mice survived significantly longer than C57BL/6 mice (A/J vs. C57BL/6: P = 0.001 and chi2 = 9.879 using a Mantel-Cox log-rank test). AKR/J mice were highly resistant and had significantly improved survival rates compared with all other strains (A/J vs. AKR/J: P = 0.00001 and chi2 = 13.568 using a Mantel-Cox log-rank test). The figure is representative of two independent experiments (n = 10 mice/group/experiment). 100% of 129sv/J and C57BL/6 mice developed CM (as described in Materials and methods), compared with 30% of A/J and 0% of AKR/J mice. (B) 129sv/J mice had significantly higher mean parasitemia than other CM-susceptible or -resistant mice on day 6 after infection (P = 0.006 using a Kruskal-Wallis test). Representative data from one of two independent experiments (n = 5 mice/group/experiment) are shown. Data are presented as means +/- SD. (C) Histopathological examination of brains from susceptible (129sv/J, B10.D2/nSnJ, and C57BL/6) and resistant (AKR/J, B10.D2/oSnJ, and BALB/c) mice, isolated on day 6 after inoculation and formalin fixed. 5-muM sections were prepared and stained with Giemsa. CM-susceptible mice displayed characteristic histological evidence of CM, including the accumulation of mononuclear cells and parasitized erythrocytes in the microvasculature. Bar, 50 muM.
###end p 17
###begin title 18
###xml 0 2 0 2 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C5</italic>
C5 sufficiency is associated with susceptibility to CM
###end title 18
###begin p 19
###xml 104 106 104 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C5</italic>
###xml 225 232 225 232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="tbl1">Table I</xref>
###xml 235 237 235 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib26">26</xref>
###xml 238 240 238 240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib28">28</xref>
###xml 358 360 358 360 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C5</italic>
###xml 396 398 396 398 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C5</italic>
###xml 433 435 433 435 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C5</italic>
###xml 502 504 502 504 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C5</italic>
###xml 634 636 634 636 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C5</italic>
###xml 684 686 684 686 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C5</italic>
###xml 863 865 863 865 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C5</italic>
###xml 894 896 894 896 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C5</italic>
###xml 1101 1103 1101 1103 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C5</italic>
###xml 1136 1138 1136 1138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib28">28</xref>
###xml 1274 1276 1274 1276 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C5</italic>
###xml 1377 1384 1377 1384 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="tbl1">Table I</xref>
###xml 1389 1395 1389 1395 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2</xref>
###xml 1454 1456 1454 1456 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C5</italic>
###xml 1469 1470 1469 1470 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib8">8</xref>
###xml 1472 1474 1472 1474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib27">27</xref>
###xml 1476 1478 1476 1478 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib29">29</xref>
###xml 1620 1622 1620 1622 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C5</italic>
###xml 1797 1799 1797 1799 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C5</italic>
###xml 1837 1839 1837 1839 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C5</italic>
###xml 2121 2129 2121 2129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 A</xref>
###xml 2166 2168 2166 2168 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C5</italic>
###xml 2642 2650 2642 2650 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 B</xref>
###xml 3124 3126 3124 3126 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C5</italic>
###xml 156 160 <span type="species:ncbi:10090">mice</span>
###xml 424 428 <span type="species:ncbi:10090">mice</span>
###xml 710 715 <span type="species:ncbi:10090">mouse</span>
###xml 808 812 <span type="species:ncbi:10090">mice</span>
###xml 907 911 <span type="species:ncbi:10090">mice</span>
###xml 1077 1081 <span type="species:ncbi:10090">mice</span>
###xml 1371 1375 <span type="species:ncbi:10090">mice</span>
###xml 1405 1409 <span type="species:ncbi:10090">mice</span>
###xml 1523 1527 <span type="species:ncbi:10090">mice</span>
###xml 2009 2013 <span type="species:ncbi:10090">mice</span>
###xml 2115 2119 <span type="species:ncbi:10090">mice</span>
###xml 2186 2190 <span type="species:ncbi:10090">mice</span>
###xml 2414 2418 <span type="species:ncbi:10090">mice</span>
###xml 2489 2493 <span type="species:ncbi:10090">mice</span>
###xml 2584 2588 <span type="species:ncbi:10090">mice</span>
###xml 2737 2741 <span type="species:ncbi:10090">mice</span>
###xml 2814 2818 <span type="species:ncbi:10090">mice</span>
###xml 2850 2854 <span type="species:ncbi:10090">mice</span>
To test the hypothesis that excessive C5a generation may confer susceptibility to CM, we determined the C5 status in the panel of susceptible and resistant mice we had phenotyped, as well as those reported in the literature (Table I) (26-28). C57BL/6, 129sv/J, and 129P3/J strains were shown to be susceptible to PbA-induced CM, and each of these strains is C5 sufficient (wild-type sequence for C5). A/J, DBA/2J, and AKR/J mice are C5 deficient (i.e., they possess a known frame-shift mutation in the C5 gene and do not express functional C5) and were significantly more resistant to PbA-induced CM. A similar association of CM with C5 sufficiency was established by determining the C5 status of other inbred mouse strains reported in the literature as susceptible or resistant to PbA. In each case, inbred mice reported to be susceptible to CM were found to be C5 sufficient. Conversely, all C5-deficient mice analyzed in this study and those reported in the literature were found to be resistant to CM. However there were two notable exceptions to this association. C3H/HeN mice are reported to be C5 sufficient but resistant to CM (28). We genotyped and phenotyped this strain together with appropriate controls and determined that it contained a wild-type sequence for C5 and was sensitive to PbA-induced CM, with a survival course similar to CM-susceptible C57BL/6 mice (Table I and Fig. 2). BALB/c mice are also reported to be resistant to CM and C5 sufficient (8, 27, 29). Because several different lines of BALB/c mice are in current use and because C5 "sufficiency" in the literature often meant only that the C5 gene did not contain the single A/J frame-shift mutation (as detected by PCR), we phenotyped the line in use in our laboratory and investigated this line for the presence of C5 sufficiency by sequencing the entire C5 gene to exclude any other point mutations, confirming gene transcription using RT-PCR, and by measuring C5a production over the course of PbA infection by ELISA. BALB/c mice were found to be resistant to the development of CM, with significantly higher survival than C57BL/6 mice (Fig. 3 A). Sequence analysis showed that the C5 gene from BALB/c mice contained no mutations in the open reading frame and therefore would have been predicted, by our hypothesis, to be susceptible to PbA-induced CM. To explain this apparent discrepancy, serum C5a levels in BALB/c and C57BL/6 mice over the course of an infection were analyzed. CM-susceptible C57BL/6 mice were shown to have significantly higher levels of C5a in the peripheral blood than BALB/c mice during infection, particularly at early time points (Fig. 3 B). These observations were also supported by RT-PCR analysis demonstrating that BALB/c mice have levels of C5 that are significantly lower than susceptible C57BL/6 mice and are similar to C5-null A/J mice (BALB/c vs. C57BL/6 mean [SD] day 1 C5 mRNA copy number = 427.1 [471] vs. 4,132 [961], P = 0.002; BALB/c vs. A/J mean [SD] day 1 C5 mRNA copy number = 427.1 [471] vs. 691.6 [480], P = 0.498). These data indicate that susceptibility to PbA-induced CM is associated with C5 sufficiency and support a role for the generation of C5a early during the course of infection as a putative mediator of CM in susceptible animals.
###end p 19
###begin p 20
###xml 12 14 12 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C5</italic>
###xml 0 81 0 81 <bold xmlns:xlink="http://www.w3.org/1999/xlink">The role of <italic>C5</italic> in the development of PbA-induced experimental CM in C3H/HeN mice.</bold>
###xml 121 123 121 123 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C5</italic>
###xml 148 150 148 150 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C5</italic>
###xml 424 426 424 426 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C5</italic>
###xml 484 485 482 483 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 559 561 557 559 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C5</italic>
###xml 614 615 610 611 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 664 665 658 659 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 758 759 752 753 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 76 80 <span type="species:ncbi:10090">mice</span>
###xml 162 166 <span type="species:ncbi:10090">mice</span>
###xml 191 195 <span type="species:ncbi:10090">mice</span>
###xml 307 311 <span type="species:ncbi:10090">mice</span>
###xml 439 443 <span type="species:ncbi:10090">mice</span>
###xml 573 577 <span type="species:ncbi:10090">mice</span>
###xml 765 769 <span type="species:ncbi:10090">mice</span>
The role of C5 in the development of PbA-induced experimental CM in C3H/HeN mice. To determine the phenotype and role of C5 in PbA infection in the C5-sufficient mice strain C3H/HeN, C3H/HeN mice, as well as control strains A/J (CM resistant) and C57BL/6 (CM susceptible), were challenged with PbA. C3H/HeN mice were susceptible to the development of CM (100% developed CM) and displayed similar mortality rates as C57BL/6 (C5-sufficient) mice (C57BL/6 vs. C3H/HeN: P = 0.2237 and chi2 = 1.481 using a log-rank test), but significantly higher rates than A/J (C5-deficient) mice (A/J vs. C3H/HeN: P = 0.0033 and chi2 = 8.656; and C57BL/6 vs. A/J: P = 0.0017 and chi2 = 9.879 using a log-rank test). The data are representative of two independent experiments (n = 10 mice/group/experiment).
###end p 20
###begin p 21
###xml 0 57 0 57 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Survival and C5a levels in BALB/c, C57BL/6, and A/J mice.</bold>
###xml 131 133 131 133 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C5</italic>
###xml 280 282 280 282 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C5</italic>
###xml 314 315 312 313 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 410 411 408 409 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 714 716 712 714 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C5</italic>
###xml 972 973 970 971 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 52 56 <span type="species:ncbi:10090">mice</span>
###xml 99 103 <span type="species:ncbi:10090">mice</span>
###xml 240 244 <span type="species:ncbi:10090">mice</span>
###xml 417 421 <span type="species:ncbi:10090">mice</span>
###xml 457 461 <span type="species:ncbi:10090">mice</span>
###xml 499 503 <span type="species:ncbi:10090">mice</span>
###xml 554 558 <span type="species:ncbi:10090">mice</span>
###xml 626 630 <span type="species:ncbi:10090">mice</span>
###xml 728 732 <span type="species:ncbi:10090">mice</span>
###xml 749 753 <span type="species:ncbi:10090">mice</span>
###xml 978 982 <span type="species:ncbi:10090">mice</span>
Survival and C5a levels in BALB/c, C57BL/6, and A/J mice. Sequence analysis showed that the BALB/c mice used in these studies were C5 sufficient and therefore, by our hypothesis, should be susceptible to PbA-induced CM. (A) However, BALB/c mice are highly resistant to CM despite C5 sufficiency (P < 0.0001 and chi2 = 16.531 using a log-rank test). The figure is representative of two independent experiments (n = 10 mice/group/experiment). 100% of C57BL/6 mice developed CM compared with 0% BALB/c mice. (B) Serum C5a levels of C57BL/6, BALB/c, and A/J mice are represented by mean OD at 405 nm (error bars show SD). C57BL/6 mice had higher circulating C5a levels, particularly on days 1 and 5 compared with A/J (C5-deficient) mice, whereas BALB/c mice only show a C5a peak at day 5 and not early in the course of PbA infection (**, P < 0.0001; *, P < 0.05; and #, P < 0.01 using a Mann-Whitney U test). The graph represents pooled data from two independent experiments (n = 5 mice/group/experiment).
###end p 21
###begin title 22
###xml 33 35 33 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C5</italic>
###xml 9 13 <span type="species:ncbi:10090">mice</span>
Congenic mice confirm a role for C5 in susceptibility to CM
###end title 22
###begin p 23
###xml 87 94 87 94 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="tbl1">Table I</xref>
###xml 132 134 132 134 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C5</italic>
###xml 232 234 232 234 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C5</italic>
###xml 462 464 462 464 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C5</italic>
###xml 562 564 562 564 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C5</italic>
###xml 604 606 604 606 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C5</italic>
###xml 632 634 632 634 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib30">30</xref>
###xml 930 932 930 932 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C5</italic>
###xml 982 984 982 984 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib30">30</xref>
###xml 1096 1098 1096 1098 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C5</italic>
###xml 1225 1227 1225 1227 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C5</italic>
###xml 1373 1375 1373 1375 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C5</italic>
###xml 1424 1425 1422 1423 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 1497 1499 1495 1497 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C5</italic>
###xml 1644 1645 1640 1641 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 1677 1683 1673 1679 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4</xref>
###xml 63 68 <span type="species:ncbi:10090">mouse</span>
###xml 380 384 <span type="species:ncbi:10090">mice</span>
###xml 408 413 <span type="species:ncbi:10090">mouse</span>
###xml 487 491 <span type="species:ncbi:10090">mice</span>
###xml 579 583 <span type="species:ncbi:10090">mice</span>
###xml 626 630 <span type="species:ncbi:10090">mice</span>
###xml 859 863 <span type="species:ncbi:10090">mice</span>
###xml 1026 1030 <span type="species:ncbi:10090">mice</span>
###xml 1183 1187 <span type="species:ncbi:10090">mice</span>
###xml 1282 1286 <span type="species:ncbi:10090">mice</span>
###xml 1387 1391 <span type="species:ncbi:10090">mice</span>
###xml 1473 1477 <span type="species:ncbi:10090">mice</span>
###xml 1603 1607 <span type="species:ncbi:10090">mice</span>
###xml 1761 1765 <span type="species:ncbi:10090">mice</span>
The phenotypic differences to PbA infection between the inbred mouse lines observed in Table I could be either the direct result of C5 sufficiency/deficiency or secondary to other genetic factors acting alone or in combination with C5. Therefore, we further explored the hypothesis that C5a contributes to the pathogenesis of CM by examining the phenotype in recombinant congenic mice and in closely related mouse lines that differ in the presence or absence of C5. Recombinant congenic mice were derived from systematic inbreeding of a double backcross between C5-deficient A/J mice and CM-susceptible, C5-sufficient C57BL/6 mice (30). In this system, each congenic strain contains a fixed set of congenic segments (12.5% of DNA from the donor parent) placed on the genetic background of the recipient parent (87.5% of DNA). Thus, AcB55 recombinant congenic mice contain 12.5% of C57BL/6 genetic material, including a functional C5 gene, on a predominantly A/J genetic background (30); conversely, BcA76 recombinant congenic mice are composed of 12.5% A/J genetic material (including the mutant C5 gene) on a C57BL/6 background. Experimental challenge of these recombinant congenic mice with PbA showed that transfer of the C5-sufficient allele onto an A/J background, as in AcB55 mice, accelerated the development of CM and fatal outcomes compared with the parental A/J (C5-deficient) mice (A/J vs. AcB55: P < 0.05 and chi2 = 4 using a log-rank test). In contrast, BcA76 mice that carry the A/J C5 deficiency allele had reduced incidence of CM and improved survival compared with the parental C57BL/6 mice (C57BL/6 vs. BcA76: P < 0.05 and chi2 = 4.038 using a log-rank test; Fig. 4). We found no difference in parasite burden between congenic AcB55 and BcA76 mice (unpublished data).
###end p 23
###begin p 24
###xml 33 35 33 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C5</italic>
###xml 0 60 0 60 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Congenic mice confirm a role for <italic>C5</italic> in susceptibility to CM.</bold>
###xml 278 280 278 280 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C5</italic>
###xml 305 307 305 307 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C5</italic>
###xml 455 457 455 457 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C5</italic>
###xml 623 624 623 624 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 654 656 654 656 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C5</italic>
###xml 715 717 715 717 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C5</italic>
###xml 760 761 758 759 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 9 13 <span type="species:ncbi:10090">mice</span>
###xml 193 197 <span type="species:ncbi:10090">mice</span>
###xml 252 256 <span type="species:ncbi:10090">mice</span>
###xml 358 362 <span type="species:ncbi:10090">mice</span>
###xml 431 435 <span type="species:ncbi:10090">mice</span>
###xml 557 561 <span type="species:ncbi:10090">mice</span>
###xml 630 634 <span type="species:ncbi:10090">mice</span>
###xml 676 680 <span type="species:ncbi:10090">mice</span>
###xml 738 742 <span type="species:ncbi:10090">mice</span>
Congenic mice confirm a role for C5 in susceptibility to CM. To further explore the hypothesis that C5a contributes to the pathogenesis of CM, we examined the phenotype in recombinant congenic mice derived from systematic inbreeding of A/J and C57BL/6 mice that differ in their C5 status. Transfer of the C5-sufficient allele onto an A/J background in AcB55 mice accelerated the development of CM and fatal outcomes, whereas BcA76 mice that carry the A/J C5 deficiency allele had reduced incidence of CM and improved survival compared with parental C57BL/6 mice. The data are representative of two independent experiments (n = 10 mice/group/experiment). C5-deficient congenic mice survive significantly longer than C5-sufficient congenic mice (P < 0.05 and chi2 = 4.038 using a log-rank test).
###end p 24
###begin p 25
###xml 217 219 217 219 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C5</italic>
###xml 290 292 290 292 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C5</italic>
###xml 522 523 520 521 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 556 564 554 562 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 A</xref>
###xml 735 743 733 741 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 B</xref>
###xml 40 44 <span type="species:ncbi:10090">mice</span>
###xml 133 137 <span type="species:ncbi:10090">mice</span>
###xml 252 256 <span type="species:ncbi:10090">mice</span>
###xml 348 352 <span type="species:ncbi:10090">mice</span>
###xml 456 460 <span type="species:ncbi:10090">mice</span>
###xml 638 642 <span type="species:ncbi:10090">mice</span>
###xml 799 803 <span type="species:ncbi:10090">mice</span>
In addition to the recombinant congenic mice, we also examined PbA-induced CM susceptibility in congenic B10.D2/nSnJ and B10.D2/oSnJ mice, which are genetically identical strains except that the B10.D2/nSnJ strain is C5 sufficient, whereas B10.D2/oSnJ mice contain the mutant allele of the C5 gene (with both on a C57BL/10 background). B10.D2/nSnJ mice were found to be susceptible to PbA-induced CM and rapidly succumbed to infection, whereas B10.D2/oSnJ mice displayed significantly improved survival (P < 0.0001 and chi2 = 12.274 using a log-rank test; Fig. 5 A). C5a levels were examined over the course of infection, and B10.D2/nSnJ mice displayed significantly higher levels of circulating C5a as early as day 1 after infection (Fig. 5 B). Together with the observations in C57BL/6 and BALB/c mice, these data further support the contention that an early and sustained induction of C5a confers susceptibility to CM.
###end p 25
###begin p 26
###xml 0 73 0 73 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Role of C5 in pathogenesis of CM in closely related B10.D2 mouse strains.</bold>
###xml 174 176 174 176 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C5</italic>
###xml 206 208 206 208 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C5</italic>
###xml 347 349 347 349 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C5</italic>
###xml 396 397 394 395 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 492 493 490 491 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 684 686 682 684 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C5</italic>
###xml 731 733 729 731 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C5</italic>
###xml 907 908 905 906 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 59 64 <span type="species:ncbi:10090">mouse</span>
###xml 220 224 <span type="species:ncbi:10090">mice</span>
###xml 265 269 <span type="species:ncbi:10090">mice</span>
###xml 361 365 <span type="species:ncbi:10090">mice</span>
###xml 498 502 <span type="species:ncbi:10090">mice</span>
###xml 542 546 <span type="species:ncbi:10090">mice</span>
###xml 593 597 <span type="species:ncbi:10090">mice</span>
###xml 712 716 <span type="species:ncbi:10090">mice</span>
###xml 758 762 <span type="species:ncbi:10090">mice</span>
###xml 913 917 <span type="species:ncbi:10090">mice</span>
Role of C5 in pathogenesis of CM in closely related B10.D2 mouse strains. To examine whether the survival difference was solely attributable to C5, the congenic B10.D2/nSnJ (C5-sufficient) and B10.D2/oSnJ (C5-deficient) mice were infected with PbA. (A) B10.D2/oSnJ mice are resistant to the development of CM and survive significantly longer than C5-sufficient mice (75 vs. 0%; P < 0.0001 and chi2 = 12.274 using a log-rank test). The figure is representative of two independent experiments (n = 8 mice/group/experiment). 100% of B10.D2/nSnJ mice developed CM compared with 25% of B10.D2/oSnJ mice. (B) Levels of serum C5a, shown as mean OD at 405 nm, were significantly increased in C5-sufficient (B10.D2/nSnJ) mice compared with C5-deficient (B10.D2/oSnJ) mice at days 1, 3, 5, and 7 after infection (*, P < 0.0001 using a Mann-Whitney U test). The data are representative of two independent experiments (n = 5 mice/group/experiment). Data are presented as means +/- SD.
###end p 26
###begin p 27
###xml 15 17 15 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C5</italic>
###xml 276 278 276 278 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C5</italic>
###xml 382 384 382 384 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C5</italic>
###xml 85 89 <span type="species:ncbi:10090">mice</span>
###xml 247 251 <span type="species:ncbi:10090">mice</span>
Association of C5 status with CM susceptibility in congenic and recombinant congenic mice support the hypothesis that C5 is an important pathological contributor to the host response. Furthermore, with confirmation in genetically identical B10.D2 mice that differ only at the C5 locus, we can remove the roles of other background genetic effects and state more confidently that the C5 gene itself influences overall outcome in experimental CM.
###end p 27
###begin title 28
###xml 13 26 13 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum</italic>
###xml 57 59 57 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pf</italic>
###xml 13 26 <span type="species:ncbi:5833">P. falciparum</span>
C5a enhances P. falciparum glycosylphosphatidylinositol (PfGPI)-induced proinflammatory responses in vitro
###end title 28
###begin p 29
###xml 95 96 95 96 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib2">2</xref>
###xml 97 98 97 98 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib6">6</xref>
###xml 105 118 105 118 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum</italic>
###xml 127 129 127 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pf</italic>
###xml 243 245 243 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib31">31</xref>
###xml 246 248 246 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib33">33</xref>
###xml 516 518 516 518 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pf</italic>
###xml 609 611 609 611 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pf</italic>
###xml 696 698 696 698 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pf</italic>
###xml 925 927 925 927 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pf</italic>
###xml 933 948 933 948 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6, A and B</xref>
###xml 989 994 989 994 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PfGPI</italic>
###xml 67 73 <span type="species:ncbi:9606">humans</span>
###xml 81 86 <span type="species:ncbi:10090">mouse</span>
###xml 105 118 <span type="species:ncbi:5833">P. falciparum</span>
###xml 432 436 <span type="species:ncbi:10090">mice</span>
###xml 580 585 <span type="species:ncbi:9606">human</span>
###xml 1131 1135 <span type="species:ncbi:10090">mice</span>
High levels of proinflammatory cytokines are associated with CM in humans and in mouse models (2-6). The P. falciparum product PfGPI has been shown to induce proinflammatory cytokine responses in a Toll-like receptor (TLR) 2-dependent manner (31-33). Because C5a may potentiate inflammatory cytokine induction to other TLR ligands, such as LPS, and because we show that peripheral C5a levels are significantly higher in susceptible mice during malaria infection, we investigated whether the presence of C5a enhances PfGPI-induced TNF and IL-6 production in vitro. The exposure of human PBMCs to HPLC-purified PfGPI in vitro induced the production of TNF and IL-6. The addition of C5a potentiated PfGPI-induced cytokine production, whereas C5aR blockade using anti-C5aR antibody significantly inhibited TNF and IL-6 production (TNF, P = 0.0064; and IL-6, P = 0.0001 using a two-way analysis of variance interaction effect [C5*PfGPI]; Fig. 6, A and B). These data indicate that C5a augments PfGPI-stimulated TNF and IL-6 production and, thus, may play a significant role in the development of the CM syndrome observed in susceptible mice.
###end p 29
###begin p 30
###xml 16 18 16 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pf</italic>
###xml 0 109 0 109 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C5a potentiates <italic>Pf</italic>GPI-induced inflammatory cytokines, and amplified responses are inhibited by C5aR blockade.</bold>
###xml 383 385 376 378 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pf</italic>
###xml 591 593 584 586 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pf</italic>
###xml 611 612 604 605 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 712 714 705 707 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pf</italic>
###xml 852 854 845 847 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pf</italic>
###xml 110 115 <span type="species:ncbi:9606">Human</span>
###xml 216 221 <span type="species:ncbi:10090">mouse</span>
###xml 258 263 <span type="species:ncbi:10090">mouse</span>
###xml 269 274 <span type="species:ncbi:9606">human</span>
C5a potentiates PfGPI-induced inflammatory cytokines, and amplified responses are inhibited by C5aR blockade. Human PBMCs were treated in three groups as follows: (a) no antibody treatment (control); (b) 5 mug/ml of mouse anti-C5aR blocking antibody; or (c) mouse anti-human IgG2a kappa isotype control. Each group was subsequently treated with 50 nM C5a +/- 300 ng/ml HPLC-purified PfGPI for 6-24 h, and the supernatants were assayed for the production of TNF and IL-6. Statistical analysis was performed by two-way analysis of variance and is representative of the interaction effect (C5a*PfGPI). A Student's t test was used to assess whether blockade of C5aR inhibited cytokine induction. (A) C5a potentiated PfGPI-induced TNF production at 6 h (**, P = 0.0064), and this effect was inhibited by blocking C5aR (***, P = 0.0008). (B) C5a potentiated PfGPI-induced IL-6 production at 24 h (***, P = 0.0001), and this effect was inhibited by C5aR blockade (**, P = 0.0013). Data are representative of two independent experiments and are presented as means +/- SEM.
###end p 30
###begin title 31
###xml 42 46 <span type="species:ncbi:10090">mice</span>
C5a and C5aR blockade rescues susceptible mice from experimental CM
###end title 31
###begin p 32
###xml 758 764 758 764 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7</xref>
###xml 488 492 <span type="species:ncbi:10090">mice</span>
###xml 543 547 <span type="species:ncbi:10090">mice</span>
###xml 690 694 <span type="species:ncbi:10090">mice</span>
The above genetic approaches implicated C5 in the pathogenesis of CM. C5 cleavage generates two effector pathways, the potent anaphylatoxin C5a and C5b, which initiates the C5b-9 membrane attack complex. To distinguish the role of C5a from the C5b-9 membrane attack complex in PbA infection and to provide direct evidence that C5a is a mediator of CM rather than a consequence of infection, we performed C5a and C5aR blockade experiments to determine whether we could protect susceptible mice from CM. Treatment of B10.D2/nSnJ (C5-sufficient) mice with anti-C5aR antibodies early in PbA infection (2 h before and 30 h after infection) conferred significant protection from CM compared with mice that received control serum (P = 0.0022 using a log-rank test; Fig. 7). Similar results were obtained using anti-C5a serum (P = 0.0019 using a log-rank test; unpublished data). These data provide the first direct evidence that the blockade of complement activation improves outcome in experimental CM and demonstrate that C5a-C5aR interactions play a central role in initiating and/or amplifying CM.
###end p 32
###begin p 33
###xml 0 74 0 74 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Blockade of C5a&#8211;C5aR protects susceptible mice from the development of CM.</bold>
###xml 225 227 225 227 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C5</italic>
###xml 276 277 276 277 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 381 382 381 382 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 406 407 404 405 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 42 46 <span type="species:ncbi:10090">mice</span>
###xml 123 127 <span type="species:ncbi:10090">mice</span>
###xml 206 210 <span type="species:ncbi:10090">mice</span>
###xml 240 244 <span type="species:ncbi:10090">mice</span>
###xml 460 464 <span type="species:ncbi:10090">mice</span>
###xml 539 543 <span type="species:ncbi:10090">mice</span>
Blockade of C5a-C5aR protects susceptible mice from the development of CM. To identify whether CM outcome in C5-sufficient mice could be modulated, C5aR was blocked using antibody treatment of PbA-infected mice. B10.D2/nSnJ (C5-sufficient) mice that received anti-C5aR serum (n = 8) were significantly protected from developing CM compared with controls receiving nonimmune serum (n = 7; P = 0.0022 and chi2 = 9.414 using a log-rank test). 100% of B10.D2/nSnJ mice treated with nonimmune serum developed CM compared with 0% of B10.D2/nSnJ mice treated with anti-C5aR serum.
###end p 33
###begin title 34
DISCUSSION
###end title 34
###begin p 35
###xml 265 267 265 267 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C5</italic>
###xml 269 275 269 275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1</xref>
###xml 280 286 280 286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2</xref>
###xml 300 302 300 302 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C5</italic>
###xml 343 345 343 345 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C5</italic>
###xml 488 490 488 490 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C5</italic>
###xml 498 504 498 504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4</xref>
###xml 509 515 509 515 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5</xref>
###xml 682 687 682 687 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PfGPI</italic>
###xml 689 695 689 695 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6</xref>
###xml 856 862 856 862 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6</xref>
###xml 867 873 867 873 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7</xref>
###xml 403 407 <span type="species:ncbi:10090">mice</span>
###xml 459 463 <span type="species:ncbi:10090">mice</span>
This study provides the first evidence implicating excessive activation of the complement system, in particular C5a, in mediating experimental CM. We demonstrate a spectrum of differential susceptibility to PbA-induced CM associated with the presence or absence of C5 (Fig. 1 and Fig. 2). A role for C5 was confirmed by reciprocal transfer of C5-defective or -sufficient alleles in recombinant congenic mice and by parasite challenge of genetically identical mice that differ only at the C5 locus (Fig. 4 and Fig. 5). In vitro experiments suggest that the mechanism by which C5a contributes to CM includes the potentiation of host inflammatory responses to malaria products such as PfGPI (Fig. 6). Additionally, our findings that disruption of C5a-C5aR interactions blocks augmented inflammatory responses in vitro and leads to protection from CM in vivo (Fig. 6 and Fig. 7) demonstrate that complement activation has a pivotal and causative role in mediating or amplifying the CM syndrome. Collectively, these data provide direct evidence for a role for C5a in the development of CM in the PbA model and suggest a potential role for excessive complement activation in the pathogenesis of CM.
###end p 35
###begin p 36
###xml 626 628 626 628 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib17">17</xref>
###xml 630 632 630 632 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib19">19</xref>
###xml 634 636 634 636 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib21">21</xref>
###xml 1008 1010 1008 1010 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib21">21</xref>
###xml 1012 1014 1012 1014 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib34">34</xref>
###xml 1015 1017 1015 1017 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib36">36</xref>
###xml 1378 1380 1378 1380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib37">37</xref>
###xml 1381 1383 1381 1383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib39">39</xref>
###xml 1537 1538 1537 1538 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib3">3</xref>
###xml 1540 1542 1540 1542 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib10">10</xref>
###xml 1544 1546 1544 1546 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib32">32</xref>
###xml 1548 1550 1548 1550 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib33">33</xref>
###xml 1579 1581 1579 1581 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pf</italic>
###xml 1662 1664 1662 1664 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib31">31</xref>
###xml 1665 1667 1665 1667 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib33">33</xref>
###xml 1711 1713 1711 1713 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pf</italic>
###xml 1749 1755 1749 1755 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6</xref>
###xml 1778 1780 1778 1780 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib40">40</xref>
###xml 1781 1783 1781 1783 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib42">42</xref>
###xml 1920 1921 1920 1921 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib3">3</xref>
###xml 1923 1925 1923 1925 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib32">32</xref>
###xml 1927 1929 1927 1929 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib43">43</xref>
###xml 1931 1933 1931 1933 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib44">44</xref>
###xml 2105 2107 2105 2107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib45">45</xref>
###xml 1527 1532 <span type="species:ncbi:9606">human</span>
There are several putative mechanisms by which excessive complement activation might mediate or augment the pathophysiologic mechanisms underlying CM. During sepsis, activation of the complement system, particularly the generation of C5a, has been associated with several deleterious impacts on host defense, including defective phagocyte function and oxidative killing; potentiated macrophage chemokine and cytokine secretion in response to TLR ligands such as LPS, caspase activation, T cell apoptosis, and associated immunodeficiency; and enhanced secretion of proinflammatory mediators and tissue factor from endothelium (17, 19, 21). Excessive generation of C5a during severe malaria infections may contribute to similar defects in host response. C5a has been shown to up-regulate several endothelial cell adhesion molecules relevant to parasite sequestration and malaria pathogenesis, including intercellular cellular adhesion molecule 1, vascular cellular adhesion molecule 1, and P- and E-selectins (21, 34-36). Increased expression of adhesion molecules, particularly in the cerebral microvasculature, would be expected to enhance leukocyte and parasitized erythrocyte adherence to endothelium, contributing to the release of toxic mediators, disruption of microcirculatory flow and regional metabolism, and endothelial cell activation and injury that characterize CM (37-39). Similar to sepsis, dysregulated inflammatory responses to microbial products have also been implicated as key factors in the pathogenesis of human CM (3, 10, 32, 33). Parasite products such as PfGPI have been shown to induce inflammatory mediators in a TLR2-dependant manner (31-33). In this study, we show that C5a enhances PfGPI-induced inflammatory responses (Fig. 6), as it does for LPS (40-42), and may contribute to the marked inflammatory response and endothelial cell activation that are central to the pathophysiology of CM (3, 32, 43, 44). In addition, C5aRs are constitutively expressed by CNS neurons, suggesting that they may be at risk in settings of CM-associated inflammation and complement activation (45).
###end p 36
###begin p 37
###xml 133 134 133 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib8">8</xref>
###xml 136 137 136 137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib9">9</xref>
###xml 139 141 139 141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib32">32</xref>
###xml 339 340 339 340 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib7">7</xref>
###xml 341 342 341 342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib9">9</xref>
###xml 344 346 344 346 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib32">32</xref>
###xml 494 502 494 502 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 B</xref>
###xml 692 694 692 694 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib46">46</xref>
###xml 986 988 986 988 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C5</italic>
###xml 1139 1149 1139 1149 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. berghei</italic>
###xml 1211 1216 1211 1216 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Char1</italic>
###xml 1218 1223 1218 1223 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Char2</italic>
###xml 1225 1230 1225 1230 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Char3</italic>
###xml 1236 1241 1236 1241 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Char9</italic>
###xml 1281 1292 1281 1292 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. chabaudi</italic>
###xml 1308 1310 1308 1310 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib47">47</xref>
###xml 1311 1313 1311 1313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib50">50</xref>
###xml 1331 1336 1331 1336 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Berr1</italic>
###xml 1338 1343 1338 1343 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Berr3</italic>
###xml 1345 1350 1345 1350 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Berr4</italic>
###xml 1356 1360 1356 1360 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cmsc</italic>
###xml 1496 1498 1496 1498 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib26">26</xref>
###xml 1500 1502 1500 1502 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib51">51</xref>
###xml 1503 1505 1503 1505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib52">52</xref>
###xml 263 267 <span type="species:ncbi:10090">mice</span>
###xml 402 406 <span type="species:ncbi:10090">mice</span>
###xml 488 492 <span type="species:ncbi:10090">mice</span>
###xml 600 604 <span type="species:ncbi:10090">mice</span>
###xml 1139 1149 <span type="species:ncbi:5821">P. berghei</span>
###xml 1281 1292 <span type="species:ncbi:99780|species:ncbi:5825">P. chabaudi</span>
###xml 1302 1306 <span type="species:ncbi:10090">mice</span>
Several studies have reported that parasite burden does not appear to play a pivotal role in the development of CM in the PbA model (8, 9, 32). Consistent with these data, we observed no significant difference in parasitemia between CM-susceptible and -resistant mice, suggesting that C5/C5a does not significantly affect parasite burden (7-9, 32). However, we observed that highly susceptible 129sv/J mice had significantly higher parasite densities than either susceptible or resistant mice (Fig. 1 B and Fig. S1). The inability of this strain to control initial parasitemia may predispose 129sv/J mice to more severe disease and the rapid development of CM. As suggested by Amante et al. (46), these findings indicate that parasite burden may also contribute to the pathogenesis of experimental CM. Collectively, these observations indicate that CM is a complex and polygenic process, and that in highly susceptible and highly resistant strains other genetic factors, in addition to C5, contribute to the phenotypes observed. Although the precise genetic determinants regulating the control of acute blood-stage parasite replication in P. berghei are unknown, studies have identified several loci, including Char1, Char2, Char3, and Char9, in the control of peak parasitemia in P. chabaudi-infected mice (47-50); more recently, Berr1, Berr3, Berr4, and cmsc loci on chromosomes 1, 9, 4, and 17 (in the H-2 region), respectively, have been associated with the genetic control of host response (26, 51-52).
###end p 37
###begin p 38
###xml 227 228 227 228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib8">8</xref>
###xml 229 231 229 231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib10">10</xref>
###xml 232 234 232 234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib12">12</xref>
###xml 236 238 236 238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib53">53</xref>
###xml 239 241 239 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib55">55</xref>
###xml 551 555 <span type="species:ncbi:10090">mice</span>
###xml 596 600 <span type="species:ncbi:10090">mice</span>
###xml 622 626 <span type="species:ncbi:10090">mice</span>
Current evidence indicates that a tightly regulated proinflammatory response is critical in the control and resolution of malaria infection, whereas excessive and sustained inflammatory responses contribute to immunopathology (8,10-12, 53-55). Similar to inflammatory responses to infection, our findings indicate that both the timing and the peak concentrations of C5a are important in determining outcome. We show that early induction of C5 activation during the course of infection contributes to potentiated inflammatory responses and predisposes mice to the development of CM (e.g., C57BL/6 mice). Conversely, BALB/c mice do not display early activation of C5 but rather a gradual activation that may facilitate the regulated responses necessary for the control of acute PbA infection while limiting host immunopathology.
###end p 38
###begin p 39
###xml 276 278 276 278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib56">56</xref>
###xml 279 281 279 281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib58">58</xref>
###xml 50 54 <span type="species:ncbi:10090">mice</span>
###xml 146 152 <span type="species:ncbi:9606">humans</span>
###xml 259 264 <span type="species:ncbi:9606">human</span>
###xml 854 862 <span type="species:ncbi:9606">patients</span>
###xml 978 983 <span type="species:ncbi:9606">human</span>
High levels of circulating C5a in the susceptible mice are consistent with studies of severe malaria and experimental malaria challenge models in humans, which reported activation of the complement system by both the classical and alternative pathways during human infection (56-58). The observation that C5a appears very early in the course of experimental CM supports its role as a potential early mediator and also suggests that it may be a useful biomarker to predict those who will go on to develop CM. Because only a small proportion of malaria-infected individuals progress to severe disease, a predictive biomarker would be of clinical utility in identifying and more effectively allocating therapeutic resources to those at greater risk of adverse outcomes. To be valuable as a biomarker would require that C5a levels have a predictive value in patients who are at risk of CM but have not yet developed the syndrome. To define the role of C5a as a putative mediator of human CM and determine whether elevated C5a levels will be a useful biomarker will require additional study in prospective clinical trials.
###end p 39
###begin p 40
###xml 96 109 96 109 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum</italic>
###xml 121 122 121 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib2">2</xref>
###xml 233 239 233 239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7</xref>
###xml 729 742 729 742 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum</italic>
###xml 1068 1070 1068 1070 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib59">59</xref>
###xml 90 95 <span type="species:ncbi:9606">human</span>
###xml 96 109 <span type="species:ncbi:5833">P. falciparum</span>
###xml 227 231 <span type="species:ncbi:10090">mice</span>
###xml 583 588 <span type="species:ncbi:9606">human</span>
###xml 688 693 <span type="species:ncbi:9606">human</span>
###xml 729 742 <span type="species:ncbi:5833">P. falciparum</span>
###xml 818 824 <span type="species:ncbi:9606">humans</span>
###xml 1307 1312 <span type="species:ncbi:9606">human</span>
Interventions that prevent CM would be of potential clinical benefit in the management of human P. falciparum infection (2). In this study, C5a-C5aR blockade results in significant protection against CM in infected susceptible mice (Fig. 7). Although the precise trigger of complement activation during malaria infection requires further investigation, the observations that C5a is required for the development of experimental CM and that blockade of C5a-C5aR activity early in the course of PbA infection improves outcome identify C5a-C5aR as a potential target for intervention in human severe malaria and CM. Additional studies are required to investigate the potential role of C5a in human infection, including CM induced by P. falciparum malaria. If C5a is subsequently shown to be an important mediator in CM in humans, then the availability of inhibitors of C5a-C5aR, including receptor antagonists and an FDA-approved humanized monoclonal antibody against C5, might permit direct testing of the hypothesis that C5a-C5aR blockade will improve clinical outcome (59). In summary, these data provide direct evidence for a role for C5a in the development of CM in the PbA model, and suggest a potential role for excessive complement activation and C5a generation in particular, in the pathophysiology of human CM.
###end p 40
###begin title 41
MATERIALS AND METHODS
###end title 41
###begin title 42
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice, parasites, and experimental infections.
###end title 42
###begin p 43
###xml 198 202 <span type="species:ncbi:10090">Mice</span>
###xml 334 338 <span type="species:ncbi:10090">mice</span>
###xml 463 467 <span type="species:ncbi:10090">mice</span>
Experiments involving animals were reviewed and approved by the University of Toronto Animal Use Committee and were performed in compliance with current University of Toronto animal use guidelines. Mice used in this study were 8-16 wk old and were maintained under pathogen-free conditions with a 12-h light cycle. C57BL/6 and BALB/c mice were purchased from Charles River Laboratories. 129sv/J, C3H/HeN, 129P3/J, DBA/2J, A/J, AKR/J, B10.D2/oSnJ, and B10.D2/nSnJ mice were purchased from the Jackson Laboratory.
###end p 43
###begin p 44
###xml 94 96 94 96 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib29">29</xref>
###xml 98 100 98 100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib32">32</xref>
###xml 169 170 169 170 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 422 423 422 423 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib3">3</xref>
###xml 424 425 424 425 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib9">9</xref>
###xml 427 429 427 429 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib26">26</xref>
###xml 430 432 430 432 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib28">28</xref>
###xml 434 436 434 436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib46">46</xref>
###xml 438 440 438 440 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib60">60</xref>
###xml 63 67 <span type="species:ncbi:10090">mice</span>
###xml 443 447 <span type="species:ncbi:10090">Mice</span>
PbA parasites were maintained by passage through naive C57BL/6 mice, as previously described (29, 32). Experimental infections were initiated by i.p. injection of 5 x 105 PbA-parasitized erythrocytes. The course of infection was monitored twice daily for neurological symptoms including mono-, hemi-, para-, or tetraplegia, movement disorder, ataxia, hunching, convulsions, and coma, to define CM as previously described (3-9, 26-28, 46, 60). Mice were judged to have CM if they displayed these neurological criteria within days 6-10 after infection and either succumbed to infection or were humanely killed as per the requirements of our institutional animal use committee. Parasitemias were monitored using thin blood smears stained with modified Giemsa stain (Protocol Hema 3 stain set; Sigma-Aldrich) from 3 d after infection onwards. CM was confirmed by histological examination of cerebral pathology. Brain tissue was carefully removed, fixed in 10% neutral-buffered formalin, embedded, sectioned (5 muM), and stained with Giemsa or hematoxylin and eosin.
###end p 44
###begin title 45
###xml 0 2 0 2 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C5</italic>
###xml 36 38 36 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C5</italic>
###xml 54 58 <span type="species:ncbi:10090">mice</span>
C5 deficiency and sequencing of the C5 gene in BALB/c mice.
###end title 45
###begin p 46
###xml 4 6 4 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C5</italic>
###xml 89 91 89 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C5</italic>
###xml 257 259 257 259 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C5</italic>
###xml 17 21 <span type="species:ncbi:10090">mice</span>
###xml 228 232 <span type="species:ncbi:10090">mice</span>
All C5-deficient mice used in this study had a bp deletion at positions 62 and 63 of the C5 gene, which was fixed in several strains during their generation. This frame-shift caused a premature stop codon that resulted in these mice being unable to produce C5 mRNA or functional C5 protein.
###end p 46
###begin p 47
###xml 25 27 25 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Hc</italic>
###xml 29 31 29 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C5</italic>
###xml 301 303 301 303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib61">61</xref>
The coding region of the Hc (C5) gene (available from GenBank/EMBL/DDBJ under GeneID no. ) was completely sequenced from BALB/c/Cr genomic DNA. Primers were designed to amplify all coding exons and a minimum of 100 bp in each direction of the flanking introns using Primer3 (Table S1, available at ) (61). Targets were PCR amplified with Taq Platinum HiFi (Invitrogen) using 50 ng DNA per reaction in a GeneAmp PCR System 9700 (Applied Biosystems). Fragments were visualized on an agarose gel. The PCR conditions were an initial denaturation at 94degreesC for 5 min, followed by 25 cycles of denaturing at 94degreesC for 30 s, annealing at 53-59degreesC for 30 s, and extension at 68degreesC for 60 s. 5 mul of PCR product was treated with the ExoSap-IT kit containing exonuclease I and shrimp alkaline phosphotase, according to the manufacturer's instructions (GE Healthcare), to remove primers and unbound nucleotides. Purified PCR products were sequenced using the BigDye Terminator v3.0 cycle sequencing kit and an automated ABI 3700 instrument (Applied Biosystems).
###end p 47
###begin title 48
###xml 45 49 <span type="species:ncbi:10090">mice</span>
Generation of recombinant (AcB/BcA) congenic mice.
###end title 48
###begin p 49
###xml 141 143 141 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib30">30</xref>
###xml 469 471 469 471 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C5</italic>
###xml 580 582 580 582 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C5</italic>
###xml 391 395 <span type="species:ncbi:10090">mice</span>
###xml 490 494 <span type="species:ncbi:10090">mice</span>
###xml 535 539 <span type="species:ncbi:10090">mice</span>
###xml 604 608 <span type="species:ncbi:10090">mice</span>
The AcB/BcA recombinant congenic strains were derived by systematic inbreeding from a double backcross (N3) between A/J and C57BL/6 parents (30). In this breeding scheme, each of these strains derives 12.5% of its genome from either A/J or C57BL/6, fixed as a set of discrete congenic segments on the background of the other parental strain (87.5% of its genome). AcB55 recombinant congenic mice were on an A/J background containing a gene segment bearing a functional C5 gene from C57BL/6 mice. Conversely, BcA76 recombinant congenic mice carry within their congenic regions the C5 mutant gene from A/J mice on a C57BL/6 background.
###end p 49
###begin title 50
###xml 35 39 <span type="species:ncbi:10090">mice</span>
Measurement of serum C5a levels in mice.
###end title 50
###begin p 51
###xml 261 262 260 261 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 828 829 820 821 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 831 832 823 824 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 127 131 <span type="species:ncbi:10090">mice</span>
###xml 219 222 <span type="species:ncbi:10116">rat</span>
###xml 228 233 <span type="species:ncbi:10090">mouse</span>
###xml 602 605 <span type="species:ncbi:10116">rat</span>
###xml 611 616 <span type="species:ncbi:10090">mouse</span>
###xml 641 652 <span type="species:ncbi:3704">horseradish</span>
C5a levels were assayed in serum specimens from PbA-infected and uninfected B10.D2/oSnJ, B10.D2/nSnJ, C57BL/6, BALB/c, and A/J mice using a sandwich ELISA. In brief, a 96-well plate was coated with purified 2 mug/ml of rat anti-mouse C5a antibody in 0.1 M NaHPO4 coating buffer, pH 9.5 (BD Biosciences), overnight at 4degreesC. The plate was washed three times with PBS containing 0.05% Tween 20 and blocked with PBS/10% FBS for 1 h at room temperature. Samples were diluted 1:100 in blocking buffer and incubated for 2 h, followed by five washes. Bound C5a was detected using biotinylated 1 mug/ml of rat anti-mouse C5a antibody and avidin-horseradish peroxidase. Reactive C5a levels were measured using 2,2'-Azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) (Sigma-Aldrich) for 30 min, and the reaction was stopped using 2 N H2SO4. The plate was read at an OD of 405 nm.
###end p 51
###begin title 52
Real-Time RT-PCR detection of C5 mRNA levels.
###end title 52
###begin p 53
###xml 201 206 200 205 <sub xmlns:xlink="http://www.w3.org/1999/xlink">12-18</sub>
###xml 313 315 312 314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib62">62</xref>
###xml 638 640 635 637 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C5</italic>
###xml 948 950 942 944 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib63">63</xref>
###xml 249 254 <span type="species:ncbi:10090">mouse</span>
Total RNA was extracted from whole blood using RNeasy columns according to the manufacturer's instructions (QIAGEN). cDNA was synthesized from 1 mug of total RNA using Superscript II RT with Oligo (dT)12-18 primers (Invitrogen). A standard curve of mouse genomic DNA (Fermentas) was used as described previously (62). gDNA standards or cDNA were added to the real-time PCR reaction containing 1x Power SYBR Green Master Mix (Applied Biosystems) and 0.5 muM of primers (Table S2, available at ) in a final volume of 10 mul. Quantitative real-time PCR was performed using a sequence detection system (ABI Prism 7900HT; Applied Biosystems). C5 copy numbers were normalized to the housekeeping genes Glyceraldehyde 3-phosphate dehydrogenase (Gapdh), Hypoxanthine phosphoribosyl-transferase 1 (Hprt), Succinate dehydrogenase complex subunit A (Sdha), and Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta polypeptide (Ywhaz) (63).
###end p 53
###begin title 54
###xml 9 11 9 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pf</italic>
C5a- and PfGPI-induced cytokine production.
###end title 54
###begin p 55
###xml 99 100 99 100 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 454 456 452 454 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pf</italic>
###xml 472 474 470 472 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pf</italic>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 227 232 <span type="species:ncbi:10090">mouse</span>
###xml 238 243 <span type="species:ncbi:9606">human</span>
###xml 301 306 <span type="species:ncbi:10090">mouse</span>
###xml 312 317 <span type="species:ncbi:9606">human</span>
Human PBMCs were isolated from the venous blood of healthy volunteers and plated at a density of 106 cells per well. Cells were separated into three groups and treated as follows: control (no treatment), anti-CD88 (5 mug/ml of mouse anti-human CD88; Serotec), or isotype control antibody (5 mug/ml of mouse anti-human IgG2a; BD Biosciences). Within each group, cells were incubated with media (control), 50 nM C5a (Biovision), 300 ng/ml of HPLC-purified PfGPI, or C5a and PfGPI for 24 h. Supernatants were collected and assayed for TNF-alpha and IL-6 cytokine production using a cytometric bead array (BD Biosciences).
###end p 55
###begin title 56
C5a and C5aR1 blockade in PbA infection in vivo.
###end title 56
###begin p 57
###xml 193 195 193 195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib64">64</xref>
###xml 197 199 197 199 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib65">65</xref>
###xml 431 432 431 432 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 60 64 <span type="species:ncbi:10090">mice</span>
###xml 99 103 <span type="species:ncbi:9925">goat</span>
###xml 123 129 <span type="species:ncbi:9986">rabbit</span>
###xml 399 403 <span type="species:ncbi:10090">Mice</span>
###xml 478 482 <span type="species:ncbi:10090">mice</span>
###xml 560 564 <span type="species:ncbi:10090">Mice</span>
To block C5a-C5aR interactions, B10.D2/nSnJ (C5-sufficient) mice were administered either anti-C5a goat serum or anti-C5aR rabbit serum in two independent experiments, as previously described (64, 65). The treatment groups received either 0.5 ml anti-C5a or anti-C5aR serum i.p. 2 h before parasite challenge, and the control groups received 0.5 ml of corresponding nonimmune serum (control serum). Mice were challenged with 5 x 105 PbA-parasitized erythrocytes. After 30-32 h, mice received a second injection of 0.5 ml anti-C5a, anti-C5aR, or control serum. Mice were monitored for 15 d.
###end p 57
###begin title 58
Statistical analysis.
###end title 58
###begin p 59
Survival studies were analyzed using the log-rank test, parasitemias were analyzed using the Kruskal-Wallis test with Dunn's multiple comparison test, and serum C5a levels were analyzed using the Mann-Whitney U test. Data are presented as means +/- SD unless otherwise noted. All experiments were repeated at least two times.
###end p 59
###begin title 60
Online supplemental material.
###end title 60
###begin p 61
###xml 214 216 214 216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib61">61</xref>
###xml 171 175 <span type="species:ncbi:10090">mice</span>
###xml 403 407 <span type="species:ncbi:10090">mice</span>
Fig. S1 shows the parasitemia data over the course of infection for various strains infected with PbA. Table S1 shows the primers used to sequence the C5 gene from BALB/c mice. Primers were designed using Primer3 (61) to amplify all exons and a minimum of 100 bp in each direction of the flanking introns. Table S2 shows the primers used for quantitative real-time RT-PCR detection of C5 mRNA levels in mice. Online supplemental material is available at .
###end p 61
###begin title 62
Supplementary Material
###end title 62
###begin title 63
[Supplemental Material Index]
###end title 63
###begin p 64
This work was supported by a Canadian Institutes of Health Research (CIHR) Team Grant in Malaria (to K.C. Kain), operating grant MT-13721 (to K.C. Kain), Genome Canada through the Ontario Genomics Institute (K.C. Kain), the Canadian Genetics Disease Network (P. Gros), the CIHR Canada Research Chair (K.C. Kain and W.C. Liles), and National Institute of Allergy and Infectious Diseases grants AI41139 (to D.C. Gowda), GM 29507 (to P.A. Ward), GM 61656 (to P.A. Ward), and HL-31963 (to P.A. Ward).
###end p 64
###begin p 65
None of the authors have conflicting financial interests.
###end p 65

